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ABSTRACT
Theorphannuclearreceptorsmallheterodimerpartner(SHP;NR0B2)interactswithadiversearrayoftranscriptionfactorsandregulatesa
variety of cellular events such as cell proliferation, differentiation, and metabolism. However, the role of SHP in bone formation has not
yetbeenelucidated.SHPexpressionissignificantlyincreasedduringosteoblastdifferentiation,anditsexpressionispartiallyregulatedby
bone morphogenetic protein 2 (BMP-2), which plays an important role in bone formation. In our study, inhibition of SHP expression
significantly repressed BMP-2-induced osteoblast differentiation and ectopic bone formation. In accordance with these in vitro and in
vivo results, osteoblast differentiation in SHP
 /  mice primary osteoblasts was significantly repressed, and the mice showed decreased
bone mass resulting from decreased numbers of osteoblasts. Finally, SHP physically interacts and forms a complex with runt-related
transcription factor 2 (Runx2) on the osteocalcin gene promoter, and overexpression of SHP increased Runx2 transactivity via
competition with histone deacetylase 4 (HDAC4), an enzyme that inhibits DNA binding of Runx2 to its target genes. Taken together,
these results indicate that SHP acts as a novel positive regulator of bone formation by augmenting osteoblast differentiation through
regulation of the transcriptional activity of Runx2.  2010 American Society for Bone and Mineral Research.
KEY WORDS: ORPHAN NUCLEAR RECEPTOR; SMALL HETERODIMER PARTNER (SHP); OSTEOBLAST DIFFERENTIATION; BONE MORPHOGENETIC PROTEIN
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Introduction
T
he atypical orphan nuclear receptor (NR) SHP is a versatile
protein with broad cellular functions. Structurally, SHP has a
putative ligand-binding domain (LBD) that lacks a classic DNA-
binding domain (DBD) and harbors two functional LXXLL-like
motifs, which are typical of NR-binding proteins.
(1) SHP interacts
with various nuclear receptors and transcription factors, such as
the estrogen receptor (ER), peroxisome proliferator–activated
receptor (PPAR), retinoic acid receptor (RAR), liver X receptor
(LXR), Nur77, c-Jun, Smad, histone deacetylase 1 (HDAC1), and
the Swi/Snf/mSin3a corepressor complex. With the exception of
PPAR, SHP acts to downregulate the transcriptional activity of
these factors.
(2,3) These findings suggest that as a transcriptional
coregulator, SHP participates in a complex regulatory network
comprised of a variety of NRs and transcription factors. Recently,
studies have focused on the role of SHP in metabolism or
homeostasis.
(4-7) However, its function on bone metabolism has
not yet been described.
Bone formation is a well-orchestrated process of lineage-
specific differentiation events.
(8) Osteoblasts, which play pivotal
roles in bone formation, are derived from pluripotent mesench-
ymal stem cells that have the capacity to differentiate into
myocytes, adipocytes, and chondrocytes.
(9) These stem cells can
differentiate into mature osteoblasts that possess the necessary
components to form bone matrix and allow subsequent
mineralization. Osteoblast differentiation is controlled by various
hormones and cytokines, such as bone morphogenetic proteins
(BMPs), and multiple transcription factors such as Runx2, Osx,
Dlx5, Msx2, Twist, AP1 (Fos/Jun), Krox-20, Sp3, and ATF4.
(10,11)
Among these, BMPs are the primary regulators of osteoblast
differentiation.
(12) As a member of the transforming growth
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262factor b (TGF-b) superfamily, the signal transduction by BMPs
occurs through the activation of serine/threonine kinase
receptors, which are classified as either type I or type II. After
ligand binding, they form a heterotetrameric activated receptor
complexandrelay thesignal fromthe receptor totarget genesin
the nucleus.
Runx2, also called Cbfa1, is a member of the runt domain gene
family.
(13) These proteins play a major role in osteoblast
differentiation by promoting the differentiation of undifferen-
tiated mesenchymal cells into osteoblasts through regulation of
various factors such as type I collagen (Col I), osteopontin (OPN),
bone sialoprotein (BSP), and osteocalcin (OC).
(14) Runx2 has been
shown to induce alkaline phosphatase (ALP) activity, expression
of bone matrix protein genes, and mineralization in immature
mesenchymal cells and osteoblastic cells in vitro.
(15–17) During
osteoblast differentiation, Runx2 interacts with diverse transcrip-
tion factors
(18) and recruits both coactivators (e.g., p300, HES-1,
and YAP) and corepressors (e.g., TLE, mSin3a, and HDACs) to
form a complex on its target promoter.
(19–22)
Recently, it has been reported that various NRs are involved in
osteoblast differentiation and bone formation. Activation of
androgen receptors stimulates BSP gene transcription via cAMP
response element (CRE) and AP1/glucocorticoid response
elements (GRE).
(23) Estrogen prevents bone loss via ERa,
(24)
and estrogen receptor–related receptor a (ERRa) regulates
osteopontin expression through a noncanonical ERRa response
element.
(25) In this study we investigated the effects of the
orphan nuclear receptor, SHP in osteoblast differentiation, and
our results show that SHP promotes osteoblast differentiation
and bone formation via regulation of Runx2 transactivity.
Materials and Methods
Plasmid constructions
The reporter constructs,  1.3kb OG2-Luc and 6 OSE-Luc, were
kindly provided by Dr RT Fransceschi (University of Michigan
School of Dentistry, Ann Arbor, MI, USA). The SHP-Luc construct
was described previously.
(26) Runx2 expression constructs were
kindly provided by Dr KY Lee (Chonnam National University,
Republic of Korea). The SHP expression construct was described
previously.
(27) pcDNA3/HA-ALK2,  3,  5, and  6 constructs
were kindly provided by Dr T Imamura (JFCR Cancer Institute,
Japan). The pBJ5.1/Flag-HDAC3 and -4 constructs were kindly
provided by Dr H Kook (Chonnam National University, Republic
of Korea). The HDAC4 siRNA constructs were constructed by
ligation of a 60-mer double-stranded oligonucleotide containing
5’-AATGTACGACGCCAAAGAT-3’ of the HDAC4 cDNA sequence
into the pSUPER vector digested with Bgl II and Xho I.
Preparation of primary osteoblasts
Calvariae were isolated from 10-day-old neonatal mice and
digested with 0.1% collagenase (Roche, Germany) at 378C for 30
minutes. The digested calvariae were sequentially digested four
times.
(30) The last fractions were collected and used as primary
osteoblasts.
Cell culture and induction of osteoblast differentiation
C2C12cellsweremaintainedinDMEM(Hyclone,Logan,UT,USA),
and C3H10T1/2 and MC3T3-E1 cells and primary osteoblasts
were maintained in a-minimal essential medium (a-MEM, Gibco,
Grand Island, NY, USA) supplemented with 10% fetal bovine
serum (FBS, Hyclone) and antibiotics (Hyclone). Differentiation of
osteoblasts was induced by 200ng/mL recombinant human
bone morphogenetic protein 2 (BMP-2, R&D Systems, Minnea-
polis, MN, USA), 50mg/mL ascorbic acid (AA), and 5mM
b-glycerophosphate (b-GP).
Transient transfection assay
Transient transfections using Lipofectamine Plus (Invitrogen,
Carlsbad, CA, USA) were carried out as described previously.
(28)
As an internal control, cytomegalovirus (CMV) b-galactosidase
plasmid was cotransfected in each transfection experiment, and
luciferase activity was normalized to b-galactosidase activity.
RT-PCR analysis
RT-PCR was performed using 0.8mg of total RNA. Each reaction
consisted of initial denaturation at 948C for 1 minute followed by
three-step cycling: denaturation at 948C for 30 seconds,
annealing at a temperature optimized for each primer pair for
30 seconds, and extension at 728C for 30 seconds. After the
requisite number of cycles (25 to 27 cycles), the reactions
underwent a final extension at 728C for 5 minutes. Primer
sequenses were SHP, forward (F) 50-CTTCCTCAGGAACCT-30 and
reverse (R) 50-CCCAGTGAGCCTCCT-30; OC, (F) 50-CTCCTGAGAGT-
CTGACAAAGCCTT-30 and (R) 50-GCTGTGACATCCATTACTTGC-30;
ALP, (F) 50-GATCATTCCCACGTTTTCAC-30 and (R) 50-TGCGGG-
CTTGTGGGACCTGC-30; BSP, (F) 50-ACACTTACCGAGCTTATGAGG-
30 and (R) 50-TTGCGCAGTTAGCAATAGCAC-30; Runx2, (F) 50-
GAGGGCACAAGTTCTATCTG-3’ and (R) 50-CGCTCCGGCCCA-
CAAATCTC-30; Col I, (F) 50-TCTCCACTCTTCTAGGTTCCT-30 and
(R) 50-TTGGGTCATTTCCACATGC-30; Osx, (F) 50-GAAAGGAGGCA-
CAAAGAAG-30 and (R) 50-CACCAAGGAGTAGGTGTGT-30; OSCAR,
(F) 50-CTGCTGGTAACGGATCAGCTCCCCAGA-30 and (R) 50-CCA-
AGGAGCCAGAACCTTCGAAACT-30;TRAP,(F)50-CTGGAGTGCACG-
ATGCCAGCGACA-30 and (R) 50-TCCGTGCTCGGCGATGGACCAGA-
30; NFATc1, (F) 50-CTCGAAAGACAGCACTGGAGCAT-30 and (R) 50-
CGGCTGCCTTCCGTCTCA TAG-30;andGAPDH,(F)50-ACCACAGTC-
CATGCCATCAC-30 and (R) 50-TCCACCCTGTTGCTGTA-30. Although
all results obtained from RT-PCR are, by definition, not
quantitative, apparent quantitative PCR analysis was done at
around 25 cycles with relatively high linearity using primer for
the housekeeping gene glyceraldehydes-3-phophate dehydro-
genase (GAPDH) toward the possible comparative reference.
Chromatin immunoprecipitation (ChIP) assay
C2C12 or 293T cells were cotransfected with the designated
expression constructs and –1.3 kb OG2-Luc reporter gene. Then,
48 hours after transfection, ChIP assays were performed as
described previously.
(28) The primer sequences for the Runx2-
binding region of the OG2 were as follows: (F) 50-GAGGACAT-
TACTGAACAC-30 and (R) 50-CAGTGGGTCAAACCCAAA -30.
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virus infection
The adenoviral vectors for full-length SHP (Ad-SHP) and SHP
siRNA (Ad-siSHP) were described previously.
(27,28) Ad-BMP and
Ad-Runx2 were described previously.
(29) Briefly, cells were
infected at the designated multiplicity of infection (MOI) using
indicated viruses in no serum for 4 hours. Following viral
infection, an equivalent volume of medium containing 4% FBS
was added, and cells were incubated for an additional 24 hours
before osteogenic medium treatment containing AA (50mg/mL)
and b-GP (5mM) in the presence of BMP-2 (200ng/mL).
Alkaline phosphatase activity and osteocalcin production
assays
ALP activity was measured in cell layers using p-nitrophenyl
phosphate substrate as described previously.
(31) ALP activity was
normalized with DNA that was measured by a PicoGreen dsDNA
quantitation kit (Molecular Probes, Eugene, OR, USA). The
amount of osteocalcin (OC) secreted into the culture medium
was determined using a mouse OC ELISA kit (Biomedical
Technologies, Inc., Stoughton, MA, USA) according to the
manufacturer’s instructions.
Alizarin red staining
Cells were fixed with 70% ethanol, rinsed three times with
deionized water, and then treated with a 40mMalizarin red stain
(AR-S) solution (pH 4.2) for 10 minutes. Stained cultures
were photographed and then quantitatively extracted using
10% (w/v) cetylpyridinium chloride (CPC) in 10mM sodium
phosphate (pH 7.0) for 15 minutes.
Osteoclast differentiation
Murine osteoclasts were prepared from bone marrow cells and
cultured in a-MEM containing 10% FBS with M-CSF (5ng/mL) for
16 hours. Nonadherent cells were harvested and cultured for
3 days with M-CSF (30ng/mL). Floating cells were removed, and
the attached cells were used as osteoclast precursors [bone
marrow–derived monocyte/macrophage lineage cells (BMMs)].
To generate osteoclasts, BMMs were cultured with M-CSF (30ng/
mL) and indicated amounts of RANKL for 3 days. Cultured cells
were fixed and stained for tartrate-resistant acid phosphatase
(TRAP), and TRAP-positive multinuclear cells (TRAPþ MNCs)
containing more than three nuclei were counted by Leica DMIRB
microscope equipped with an N Plan 10 /0.25 numerical
aperture objective lens (Leica, Wetzlar, Germany). Images were
obtained using a Leica IM50 camera and Leica IM 4.0 software
(Leica, Cambridge, UK).
X-ray and micro-computed tomographic (mCT) scanning
C57BL/6J mice (male, 6 weeks old) were injected with a fixed
dose of 5 10
10 PN (particle number) of the designated
adenoviral constructs in the thigh muscle: mock virus (n¼3),
Ad-BMP-2 (n¼3), Ad-siSHP (n¼3), and Ad-BMP-2 plus Ad-siSHP
(n¼3) diluted in PBS. Ectopic bone formation was monitored by
radiographic apparatus (Hi-Tex, Osaka, Japan) at 35kVp and
400mA (2D). Microarchitecture of the femoral and tibial
trabecular bone was investigated using mCT (Skyscan 1172,
Skyscan, Kontich, Belgium) in cone-beam acquisition mode. The
X-ray source was set at 50kV and 200 A with a pixel size of
17.09mm.Exposuretimewas1.2seconds.Four-hundredandfifty
projections were acquired over an angular range of 180 degrees
(angular step of 0.4degree). The image slices werereconstructed
using 3D CT analyzer software (CTAN, Skyscan). Trabecular
morphometry was characterized by measuring the bone volume
fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number
(Tb.N), and trabecular separation (Tb.Sp). For static histomor-
phometry, the tibia from each mouse was removed and fixed in
4% paraformaldehyde in PBS at 48C, decalcified, dehydrated
in progressive concentrations of ethanol, cleared in xylene, and
embedded in paraffin. Quantification of osteoblasts and
osteoclasts was performed in paraffin-embedded tissue, as
described previously.
(32)
Animals
SHP null (SHP
 / ) mice on a C57BL/6 and 129/Sv mixed
background were backcrossed with C57BL/6 mice 10 times to
generate congenic C57BL/6SHP
 /  mice, as described pre-
viously.
(33) Age-matched male SHP
 /  congenic and wild-type
(WT) C57BL/6 mice were used throughout this study. All animal
studies were carried out under the guidelines of the Chonnam
National University Animal Care and Use Committee.
Statistical analysis
Allexperiments wererepeatedatleastthree times,andStudent’s
t test was used to measure statistically significant differences
among groups. Unless otherwise indicated, experimental data
are expressed as means SD of triplicate independent samples.
Results
SHP gene expression is increased during osteoblast
differentiation and regulated by BMP-2
SHP is expressed in various tissues and involved in a complex
regulatory network comprised of a variety of NRs and
transcription factors.
(2,3) To assess whether SHP might play a
functional role in bone metabolism, the endogenous expression
of SHP was examined in various progenitor cells. As shown in
Fig.1A,SHP isexpressed inC3H10T1/2pluripotentmesenchymal
cells, C2C12 myoblastic cells, mouse primary osteoblasts, and
MC3T3-E1 preosteoblastic cells. During the osteoblastic differ-
entiation process, the expression levels of ALP and OC, which are
typical osteoblast differentiation markers, were increased.
(34)
Importantly, the expression pattern of SHP was similar to that of
ALP and OC after treatment with ascorbic acid (AA) and b-
glycerophosphate (b-GP), which are classic inducers of osteo-
blast differentiation (Fig. 1B). The TGF-b superfamily member
BMP-2playsacentralroleduringosteoblastdifferentiation.
(12)To
investigate the expression level of SHP during BMP-2-dependent
osteoblasts differentiation, C2C12 cells were treated with BMP-2
in combination with AA and b-GP for 6 days. As shown in
Fig. 1C, the addition of BMP-2 significantly induced the
expression of SHP, in conjunction with other osteoblast
differentiation markers, at a much earlier time point. These
264 Journal of Bone and Mineral Research JEONG ET AL.results indicate that the expression of SHP is temporally
regulated during osteoblast differentiation, suggesting that
SHP may play a specific role in bone development.
As shown in Fig. 1C, the expression level of SHP also was
increased by BMP-2, suggesting that BMP-2 is a potential
regulator of SHP gene expression. Therefore, we examined SHP
promoter activity in response to either treatment with
exogenous BMP-2 or expression of various activated BMP
receptors in C2C12 cells. As shown in Fig. 1D, SHP promoter
reporter activity was increased by treatment with BMP-2 in a
dose-dependent manner. To determine whether the increased
SHP promoter activity is dependent on BMP signaling,
constitutively active forms of TGF-b superfamily such as type
IA activin receptor (ALK2), BMP type IA receptor (ALK3), TGF-b
type I receptor (ALK5), and BMP type IB receptor (ALK6) were
cotransfected with a SHP promoter reporter construct. The data
showed that only ALK3 and -6, which are typical BMP receptors,
activated SHP promoter activity (see Fig. 1E), suggesting that
BMP-2 is a potential regulator of SHP.
Inhibition of SHP expression represses expression of
BMP2–induced osteoblast differentiation markers
BMP-2 promotes osteoblast differentiation via regulation of the
expression of various osteoblast-specific genes.
(35,36) To deter-
mine if there is a direct effect of SHP on BMP-2-induced
osteoblast differentiation, SHP gene expression was inhibited by
infecting C3H10T1/2 cells with an adenoviral vector expressing
SHP small interfering RNA (Ad-siSHP). The expression of
osteoblast differentiation markers then was observed in the
presence of BMP-2. As shown in Figure 2A, adenovirus-mediated
overexpression of BMP-2 in control cells induced the expression
of osteoblast-specific genes such as ALP, OC, BSP, and Col I in
conjunction with an increase in SHP expression, whereas
expression of these differentiation marker genes was signifi-
cantly repressed by Ad-siSHP. Interestingly, the inhibition of SHP
also decreased the marker gene expression without BMP-2. As a
functional analysis, we further confirmed the changes in ALP
activity and OC production by Ad-siSHP-mediated inhibition of
Fig. 1. SHP gene expression during osteoblast differentiation and SHP promoter activity induced by BMP-2. (A) Endogenous expression of SHP in various
progenitor cells. Total RNAs were isolatedfrom the 3-day-cultured cells and used for RT-PCR with mouse SHP and GAPDH primers. (B) mRNA expression of
osteoblast-specific genes and SHP in primary (18) osteoblast differentiation. Mouse primary osteoblasts were maintainedfor 25 days in a-MEM containing
AA (50mg/mL) andb-GP (5mM).At the designatedtime points,cells wereharvestedfor total RNA isolation,andRT-PCR was performedwith theindicated
primers. The lower figure demonstrates the endogenous expression of SHP in the absence of AA and b-GP as a control. (C) mRNA expression of ALP, OC,
and SHP during osteoblast differentiation by BMP-2. C2C12 cells were cultured for 6 days in DMEM containing 200ng/mL of BMP-2 in the presence of AA
andb-GP.Atthedesignatedtimepoints,totalRNAswereisolatedandusedforRT-PCR.(D,E)SHPpromoteractivitybyBMP-2andconstitutiveactiveforms
oftheBMPreceptor.C2C12cellsweretransfectedwith100ngofSHP-Lucreporterplasmidand50ngofpCMV-b-galactosidaseasaninternalcontrolinthe
presence of the indicated amounts of recombinant human BMP-2 (D) or 100ng of pcDNA3/HA-ALK2, -3, -5, and -6 (E). Reporter assays were performed as
described in ‘‘Materials and Methods.’’ a, b¼p<.03.
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2-induced ALP activity and OC production were significantly
reduced by Ad-siSHP. Taken together, these results indicate that
inhibitionofSHPgeneexpressionresultsindecreasedexpression
of ALP, OC, BSP and Col I, all of which are involved in the
regulation of osteoblast differentiation.
SHP regulates BMP-2-induced mineralization and
ectopic bone formation
Extracellular matrix mineralization is the most important
phenomenon in bone formation and is regulated by various
osteogenic factors.
(37) The preceding results revealed that SHP
regulates osteoblast differentiation. To verify the functional
influences of SHP on BMP-2-induced mineralization, we infected
C2C12 with Ad-SHP or Ad-siSHP in the presence or absence of
BMP-2 and then assessed the amount of mineralization by
alizarin red staining. As shown in Figure 3A, adenovirus-
mediated SHP overexpression moderately increased mineralized
nodule formation even in the absence of BMP-2, whereas
overexpression of SHP in combination with the addition of BMP-
2 dramatically increased the amount of mineralization compared
with BMP-2 alone. However, BMP-2-induced mineralization was
significantly decreased by inhibition of SHP expression, even in
the presence of added BMP-2. These results suggest that SHP is
physiologically involved in BMP-2-induced mineralization. To
confirm this result in a different cell line, weexamined the effects
of SHP expression on BMP-2-induced mineralized nodule
formation in C3H10T1/2 cells. As shown in Figure 3B, Ad-BMP-
2 dramatically increased mineralization, whereas inhibition of
SHP expression with Ad-siSHP repressed the mineralization in a
dose-dependent manner. In addition, BMP-2-induced OC
production also was significantly decreased by Ad-siSHP during
cell culture (see Fig. 3C). These results indicate that SHP has a
functional role in BMP-2-induced mineralization. It is well
reported that subcutaneous or intramuscular administration of
BMP-2 induces ectopic cartilage and bone formation.
(12) To
determine the effect of SHP on intramuscular bone formation in
vivo, BMP-2-induced ectopic bone formation was analyzed in
conjunction with Ad-siSHP intramuscular injection. Radiographic
(X-ray, 2D) and mCT (3D) analysis revealed that adenovirus-
mediated BMP-2 expression profoundly induced ectopic bone
formation in the thigh muscle, whereas inhibition of SHP
expression significantly decreased the bone formation (see
Fig.3D).Takentogether, theseresults indicatethat SHP regulates
the expression of osteoblast-specific genes and the mineraliza-
tion of potent osteoblastic cells that contribute to substantial
bone formation.
Repressed osteoblast differentiation in SHP
 /  mouse
To explore the physiologic effect of SHP in an animal model, we
observed the endogenous expression profile of osteoblast
marker genes and osteoblast differentiation in the SHP
 / 
mouse. As shown in Figure 4A, the expression levels of ALP, BSP,
and osterix (OSX) were significantly decreased in SHP
 /  mouse
calvarial cells compared with WT mice. However, the expression
levels of Col I and Runx2, a major transcription factor for
osteoblast differentiation, were not significantly changed in
Fig. 2. BMP-2-induced osteoblast-specific gene expression following
inhibition of SHP expression. (A) mRNA expression of osteoblast-specific
genes by the inhibition of SHP expression. C3H10T1/2 cells were infected
with the indicated adenovirus at an MOI of 100. Mock virus was used as a
control. Then, 48 hours after infection, the cells were harvested, and total
RNA was prepared for RT-PCR with designated primers. (B, C) BMP-2-
induced ALP activity and OC production by the inhibition of SHP
expression. C2C12 cells were infected with Mock virus or Ad-siSHP in
the presence or absence of Ad-BMP-2. Three days later, cells were
harvested,andthelysatesandculturemediumwereusedforALPactivity
and OC production assays, respectively, as described in ‘‘Materials and
Methods.’’ a¼p<.001.
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 /  mice, suggesting that SHP does not participate in the
regulation of Runx2 or Col I expression. To determine the effect
ofBMP-2onSHP
 / mouseprimaryosteoblasts,isolatedcalvarial
cells were treated with AA and b-GP to induce osteoblast
differentiation in the presence or absence of BMP-2. As shown in
Figure 4B and C, BMP-2-induced ALP activity and OC production
were significantly decreased in SHP
 /  mice compared with WT
mice. In addition, mineralized nodule formation by BMP-2 was
also decreased in SHP
 /  mice (see Fig. 4D), suggesting that
the absence of SHP causes a defect in osteoblast differentiation.
These results indicate that endogenous SHP is substantially
involved in osteoblast differentiation and mineralization.
Osteoblast and osteoclast differentiations are sophisticated
and well-orchestrated processes, and proper balance between
both processes is critical for proper bone metabolism.
(38) To
examine whether SHP is involved in osteoclast differentiation,
we examined the expression of osteoclast marker genes and
tartrate resistant acid phosphatase (TRAP) staining from SHP
 / 
mouse bone marrow cells that are induced by receptor activator
of NF-kB ligand (RANKL), a key inducer of osteoclast differentia-
Fig. 3. The effectof SHPon BMP-2-induced mineralizationandectopic boneformation. (A) SHPincreasedmineralizednoduleformationinducedby BMP-
2. C2C12 cells were infected with the indicated adenovirus at an MOI of 100. The, 24 hours after infection, the medium was changed to a mineralizing
medium containing AA and b-GP in the presence or absence of BMP-2 for 6 days. (B) Ad-siSHP decreased BMP-2-induced mineralized nodule formation.
C3H10T1/2 cells were infected with the indicated adenovirus at 50 (þ) to 100 (þþ) MOI. Then, 24 hours after infection, the medium was changed to a
mineralizing medium. During the cell culture, the medium was changed every other day. After 7 days, cells were fixed and stained with alizarin red stain
(AR-S)solution,andtheAR-Sconcentrationwasmeasuredasdescribedin‘‘MaterialsandMethods.’’Therightpanelsof(A)and(B)depicttheproducedAR-
S concentrations. (C) Ad-siSHPdecreasedBMP-2-inducedOC production. At3 and6 days afteradenoviralinfection, theculturemediumwasharvested(by
the same method as in the experiment described in panel B), and the amounts of OC secreted into the culture medium were measured as described in
‘‘MaterialsandMethods.’’a,b,c¼p<.01.(D)DecreasedBMP-2-inducedectopicboneformationbytheinhibitionofSHPexpression.5 10
10PNs(particle
numbers)ofeachadenovirus was injectedintothighmuscleofmice.Fiveweeksafterinjection,ectopicboneformationwasanalyzedby X-ray(2D)or mCT
(3D). The white arrow indicates newly formed bone tissue.
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 /  mouse. (A) Endogenous mRNA expression of osteoblast-specific genes in WT and SHP
 /  mouse
primaryosteoblasts. Total RNAs were isolated and used for RT-PCR with the indicated primers. The right panel depicts the relative mRNA expression levels
of each gene from SHP
 /  mice compared with WT mice (% WT). (B–D) BMP-2-induced ALP activity (B), OC production (C), and mineralized nodule
formation (D) in WT and SHP
 /  mice. The primary osteoblasts from WT and SHP
 /  mice were maintained in a-MEM containing AA and b-GP in the
presence or absenceofBMP-2 for 9 days (for ALP andOC) or 20days (for AR-S).a,b¼p<.01. (E) TRAPstainingof mousebonemarrowcells inducedby M-
CSF and RANKL. Isolated bone marrow cells from WT and SHP
 /  mice were cultured in a-MEM containing 10% FBS with M-CSF (5ng/mL) for 16 hours. To
generate osteoclasts, the cells were cultured with M-CSF and RANKL (100ng/mL). After 3 days in culture, the cells were fixed and stained for TRAP, and
TRAP-positive multinuclear cells (TRAP
þ MNCs) containing more than three nuclei were counted under the microscope. ( F) mRNA expressions of
osteoclast-specific marker genes. Duplicate cultures, as described in panel (E), were prepared. At designated time points, the cells were harvested, and
then total RNAs were prepared for RT-PCR.
268 Journal of Bone and Mineral Research JEONG ET AL.tion.AsshowninFigure4EandF,therewasnocleardifferencein
the typical morphology of osteoclasts and the expression
patterns of marker genes such as osteoclast-associated receptor
(OSCAR), TRAP, and nuclear factor of activated T cells (NFATc1)
betweenWTandSHP
 / mousebonemarrow cells.These results
indicate that SHP has no specific role in osteoclast differentiation
and rather that it has more critical functions on osteoblast
differentiation in bone metabolism.
Decreased bone mass in the SHP
 /  mouse
To investigate the impact of SHP expression on direct bone
formation, we compared the bone mass of WT and SHP
 /  mice
by mCT analysis and histomorphometric measurements in
sections of tibiae collected at the ages of 1, 5 or 6, and 20 weeks,
respectively. As shown in Figure 5A, bone mineral density (BMD)
of tibiae from 5- and 20-week-old SHP
 /  mice was significantly
decreased compared with WT mice. Moreover, the bone mineral
volume (BV/TV) also was decreased in same-aged SHP
 /  mice
(see Fig. 5B). However, there was no comparable change in bone
density or BV/TV of 1-week-old SHP
 /  mice, indicating that SHP
functions primarily at a relatively late stage of bone develop-
ment. To investigate more detailed static bone histomorpho-
metry, we measured each degree of trabecular bone number
(Tb. No.), thickness (Tb. Th.), and separation (Tb. Sp.) in 6-week-
old WT and SHP
 /  mice. Similar to the findings in femurs, SHP
 /
  mice tibiae exhibited a decrease in trabecular number and
thickness as well as an increase in trabecular bone separation
(see Fig.5C–E). Furthermore, the numberofosteoblasts per bone
surface was significantly reduced in SHP
 /  mice (see Fig. 5F). In
addition, the growth plate of the SHP
 /  mice had considerably
fewer chondrocytes than WT mice, which have an elongated
region of hypertrophic cartilage (see Fig. 5F, left panel).
Interestingly, the histomorphometric analysis showed that the
number of osteoclasts also was reduced in SHP
 /  mice (see
Fig. 5G). 3D mCT measurements especially revealed a significant
decrease in trabecular thickness in SHP
 /  mice (see
Fig. 5H and I). Collectively, these results suggest that SHP is
involved in determining substantial bone architecture.
SHP physically interacts with Runx2 and
regulates its transactivity
To determine the mechanism by which SHP promotes osteoblast
differentiation, we examined the effect of SHP on the
transactivity of Runx2 because BMP-2-Runx2 cascade is
important for the differentiation of mesenchymal stem cells
into the osteoblast lineage.
(18) Moreover, bone-specific expres-
sion of OC is regulated principally by Runx2.
(39) To examine
whether SHP affects Runx2 function, the effect on Runx2
transactivity by SHP expression was analyzed in C3H10T1/2 cells.
As shown in Figure 6A, the Runx2-dependent reporter activity of
OG2-Luc was enhanced by overexpression of SHP. In C2C12 cells
transfected with a 6 OSE-Luc, SHP also significantly increased
Runx2 transactivity in a dose-dependant manner (see Fig. 6B). To
gain insights into the mechanism by which SHP increases Runx2
transactivity, we examined the physical interaction between SHP
and Runx2 using an in vivo glutathione-S-transferase (GST) pull-
down assay. As shown in Figure 6C, SHP physically interacted
with Runx2 protein, showing that SHP activates Runx2
transactivity by direct interaction. To determine the interacting
region of Runx2, we performed immunoprecipitation (IP) assay
with different fragments of Runx2 proteins. As shown in
Figure 6D, SHP strongly interacted with the Runt (R) domain,
although there was weaker interaction with the amino terminus
(N) of Runx2. To further examine whether there is any complex
formation between SHP and Runx2 on their target gene
promoter, ChIP assay was performed. As shown in Figure 6E,
SHP interacted with Runx2, which bound to its target binding
sequences of osteocalcin gene promoter. Consistent with these
results, Ad-Runx2-mediated ALP activity was markedly repressed
by the inhibition of SHP expression, whereas overexpression of
SHP additively increased Runx2-dependent ALP activity (see
Fig. 6F). We further examined the Runx2 protein levels in primary
osteoblasts of WT and SHP
 /  mice. However, we could not
detect any difference in Runx2 protein levels (data not shown).
Taken together, these results indicate that SHP may regulate
osteoblast differentiation through enhancement of Runx2
activity not via regulation of Runx2 protein level.
SHP regulates Runx2 transactivity via competition
with HDAC4
Previous studies reported that various coactivators or corepres-
sors interact with Runx2 to promote or repress Runx2
transactivity.
(19,21,22) To examine whether SHP has any effect
on transcriptional corepressors of Runx2, we used a transient
transfection assay in C2C12 cells. The selected corepressors of
Runx2, such as mSin3a, HDAC3, and HDAC4, significantly
repressed Runx2 transactivity (data not shown). Among the
corepressors, HDAC4 was the most strongly affected by SHP,
which showed a significant recovering function for the HDAC4’s
repressive activity (Fig. 7A). Moreover, SHP competed with
HDAC4foraninfluenceoverRunx2transactivity(seeFig.7B),and
inhibition of endogenous HDAC4 increased Runx2 transactivity
(see Fig. 7C), demonstrating that HDAC4 is a substantial
corepressor of Runx2. A previous study reported that HDAC4
inhibits Runx2 from binding to its target gene, such as
osteocalcin.
(40) To further examine whether SHP competes with
HDAC4 in vivo, we performed a ChIP assay in C2C12 cells. As
shown in Figure 7D, expression of HDAC4 inhibited Runx2 DNA
bindingtotheosteocalcingenepromoter,whereasexpressionof
SHP relieved the repressed DNA binding of Runx2 in a dose-
dependent manner. These results indicate that SHP promotes
Runx2 transactivity through competition with HDAC4.
Discussion
Osteoblast differentiation and bone matrix formation are finely
tuned processes that are tightly regulated by a variety of
transcription factors. Recently, it has been reported that several
NRs regulate osteoblast differentiation via promotion of
osteogenic gene expression.
(23,25) In this study, we investigated
a role of the orphan NR SHP in bone formation. In osteoblastic
cells, BMP-2 significantly induced SHP gene expression and
induction of osteoblast differentiation as well as increased SHP
promoter activity. As a member of the TGF-b superfamily, BMP-2
SHP REGULATES OSTEOBLASTIC BONE FORMATION Journal of Bone and Mineral Research 269Fig. 5. Decreased bone mass in SHP
 /  mice. (A, B) Bone mineral density (BMD) and bone volume/total volume (BV/TV) of tibiae from 1-, 5-. and 20-week-
old male WT (n¼6) and SHP
 /  mice (n¼6) using mCT, respectively. (C–E) Trabecular bone number (Tb. No.), trabecular thickness (Tb. Th), and trabecular
separation (Tb. Sp) of tibiae. (F, G) Histomorphometric analysis of bone formation (left) and quantification of osteoblasts and osteoclasts per bone surface
(right), respectively. (H, I) Representative cross sections of the tibia and femur shaft (top) and the bone density of the cortical and trabecular region
(bottom), respectively. Six-week-old male WT and SHP
 /  mice were used in experiments C through I (n¼4). a, b, c¼p<.03. NS¼nonsignificant.
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(12) through multiple downstream pathways, including
the Smad pathway, which is initiated by phosphorylation of
Smad proteins by type I receptors and the mitogen-activated
protein kinase (MAPK) pathway. In either case, the ultimate
consequence of BMP-2 signaling is the activation of gene
transcription, which promotes osteoblast differentiation and
bone formation. Therefore, the expression of SHP may be
regulated by a certain mediator(s) that is involved in the BMP
signaling pathway. To identify the potential mediator, we
examined the effects of several regulators that are activated by
BMP-2, such as Smads, JNK, c-Jun, Dlx5, Msx2, Runx2, and Osx, on
SHP promoter activity. However, we were unable to identify an
activator of the SHP promoter construct (data not shown).
Meanwhile, some of our results revealed that AA and b-GP
induced SHP expression in mouse calvarial cells (see Fig. 1B) and
that SHP overexpression by Ad-SHP also induced mineralization
of osteoblastic cells, even in the absence of BMP-2 (see Fig. 3A).
Fig. 6. RegulationofRunx2activitybyassociationwithSHP.(A,B)SHPincreasesRunx2transactivity.C3H10T1/2(A)andC2C12(B)cellswerecotransfected
with 200ng of the indicated luciferase reporter and 100ng of Runx2 together with 100ng (þ) or 200ng (þþ) of HA-SHP. (C) Physical interaction of SHP
withRunx2.InvivoGSTpull-downassaywasperformedwith293Tcellsasdescribedin‘‘MaterialsandMethods.’’(D)MappingtheSHPinteractiondomains
of Runx2. 293T cellswere cotransfected with Myc-taggeddifferent domains of Runx2 (N: 1–92;R: 93–220; C: 221–513 amino acids) and HA-SHPexpression
vectors. Immunoprecipitation (IP) assay was performed with anti-HA and control IgG. (E) Complex formation of Runx2 and SHP on osteocalcin gene (OG2)
promoterregion.293T cellswerecotransfected with3mgof HA-SHPandMyc-Runx2togetherwith OG2promoter. Then48 hoursaftertransfection, whole
cell lysates were prepared and subjected to IP using respective antibodies, and the isolated DNA was analyzed by PCR. Primers were designed to amplify
the Runx2-binding region on the OG2 promoter. Ten percent of the input whole cell lysate was used as the input control. ( F) The effects of SHP on the
Runx2-mediated ALP activity. C3H10T1/2 cells were infected with the indicated adenovirus at an MOI of 100. Then, 24 hours after infection, the medium
was changed to the osteogenic medium. Eight days later, ALP activity was determined as described previously. a, b¼p<.01.
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BMP-2-independent modulator or an alternative BMP-2-depen-
dent pathway that promotes SHP gene expression, and the
possibility has lead us to begin the search for a novel SHP
regulator.
The fact that SHP expression is upregulated during osteoblast
differentiation motivated us to speculate that SHP may have a
positive role in bone metabolism, in contrast to its classic
functions. In order to determine the endogenous role of SHP in
bone differentiation, we observed BMP-2-induced osteoblast
differentiation patterns in an SHP-deficient state becausee
overexpression of SHP strongly augmented mineralized nodule
formation induced by BMP-2 (see Fig. 3A). The data demon-
strated that inhibition of SHP expression reduced the expression
of osteoblast-specific marker genes, mineralization of osteo-
blasts, and ectopic bone formation in the mouse. These results
are in agreement with the results obtained from in vivo
experiments in SHP
 /  mice that revealed reduced osteoblast
differentiation patterns and decreased bone mass. Interestingly,
loss of SHP per se resulted in the reduction of osteogenesis
regardless ofBMP-2 existence. Inaddition, loss of SHP expression
in primary osteoblasts, which show relatively high SHP
expression (see Figs. 1A and 4A), reduced the expression of
ALP activity and mineralization without BMP-2 (see Fig. 4B–D),
but did not produce any significant changes in C2C12 cells,
which show relatively low levels of SHP expression without BMP-
2 (see Fig. 2B, C). This result indicates that SHP acts directly on
osteogenesis with BMP-2-dependent or -independent signaling
and suggest that SHP differentially regulates osteoblast
differentiation in a cell-type- and a context-dependent manner.
In particular, trabecular BMDs of the tibia and femur were
significantlydecreasedinSHP
 / mice,muchmoresothaninthe
corticalbone.Theseresultsindicatethatreducedbonemassmay
be due to decreased trabecular BMD. Meanwhile, a lack of SHP
had no significant effect on bone mass in young mice (1week
after birth), which suggests that SHP is involved in the later
stages of bone development. Recent study demonstrated that
BMP-2 activity is required for postnatal bone physiology.
(41)
Therefore, our results indicate that the potential existence of a
regulator ofSHP expression or activation whose activity depends
on developmental cues in connection with BMP-2 and that SHP
may cooperate with BMP-2 for the late developmental stage in
vivo. Bone metabolism is determined by the balance between
osteoblasticcellfunctionforboneformationandosteoclasticcell
function for bone resorption, and various regulators act to
maintain that balance.
(42,43) With regard to osteoclast differ-
entiation, loss of SHP expression had no significant effect on
cellular development or on the expression of osteoclast specific
Fig. 7. RegulationofRunx2 transactivity by SHPvia competition withHDAC4. (A, B) The effectsof SHPon the transcriptional corepressors of Runx2.C2C12
cellswere cotransfected with 200ng of the six copies OSE-Lucreporter and100ng of Runx2 together with 100ng (þ) or 200ng (þþ) of mSin3a, HDAC3or
-4andSHPexpressionvectors.(C)RepressionofendogenousHDAC4expressionincreasedRunx2transactivity.C2C12cellswerecotransfectedwith200ng
of the reporter and Runx2 together with different doses of siHDAC4and/or SHP. Reporter assay was performed as described previously. (D) SHP recovers
the repressed DNA binding of Runx2 by HDAC4. C2C12 cells were cotransfected with 0.5mg( þ)o r1mg( þþ) of Myc-Runx2, Flag-HDAC4, and HA-SHP
together with 0.5mg of OG2 promoter. Then, 48 hours after transfection, whole cell lysates were prepared and subjected to ChIP as described previously.
a, b, c¼p<.01
272 Journal of Bone and Mineral Research JEONG ET AL.marker genes such as OSCAR, TRAP, and NFATc1 (see Fig. 4E, F).
However, our in vivo result showed that loss of SHP causes
decreased osteoclast numbers as well as osteoblast numbers
(seeFig.5F,G).TheseresultssuggestthatSHPhasnodirecteffect
on osteoclast differentiation, but it has an indirect effect on
osteoclast number owing to the inhibition of osteoclastogenesis,
which is partially regulated by mature osteoblasts.
In general, SHP functions primarily as a transcriptional
corepressor by interacting with various transcriptional factors,
including nuclear receptors.
(2) However, in this study, SHP was
characterized as a positive regulator of bone differentiation, a
finding that is inconsistent with its classic function. Among SHP
target transcription factors, members of the PPAR family are
known to be positive regulatory partners, and it has been
reported that SHP is an endogenous enhancer of the
transcriptional activity of PPARa
(44) and that the activation of
PPARg is due in part to the inhibition of NCoR activity by SHP.
(45)
Previously, we have investigated the relation between SHP and
PPARg during adipogenic process in preadipocyte 3T3-L1.
However, the expression of SHP was decreased during
adipogenesis (data not shown). Thus this result suggests that
SHP may not be involved in adipogenesis in connection with
PPARg. Because SHP does not possess a DNA-binding domain, it
may exert its role in bone formation through interaction with a
specific coregulator. As a target regulator of SHP activity, we
identified HDAC4, which blocks DNA binding of Runx2 to its
target gene promoter. Our finding suggests that SHP uses a
competition mechanism to regulate bone metabolism, which is
similar to the regulation mechanism of SHP on PPARg
transactivity. Recently, it was reported that SHP increases gene
expression of cyclooxygenase-2 (COX-2) via the sequential
transcriptional induction of a caudal-related homeobox gene
(CDX1) in human gastric cancer cells.
(46) With regard to its
controversial regulatory propensity, these reports suggest that
SHP may participate differently in various cellular functions
depending on the cell type. Previous reports demonstrated that
HDAC4
 /  mice exhibit a phenotype similar to that observed
in mice with constitutive expression of Runx2 in chondrocytes,
and HDAC4, which is expressed in prehypertrophic chondro-
cytes, regulates chondrocytes hypertrophy and endochondral
bone formation by inhibiting the Runx2-binding activity.
(40)
In fact, endochonral bone formation begins with condensation
of mesenchymal cells and their subsequent differentiation
into chondrocytes, which organize into a template of the
eventual bone comprised of a succession of proliferating,
prehypertrophic, and hypertrophic regions.
(47) As shown in
Figure 5F, SHP
 /  mice showed considerably fewer chondro-
cytes than WT mice. Thus our results also support the hypothesis
that the transactivity of Runx2 is regulated by HDAC4 and that
inhibition of HDAC4 promotes osteoblast differentiation and
bone formation.
This study presents new evidence that the orphan nuclear
receptor SHP is a novel positive regulator of osteoblast
differentiation and bone formation. These findings may open
new areas for exploring the molecular mechanisms that underlie
osteoblast differentiation by orphan nuclear receptors. Further,
these findings also may contribute to the development of
therapies based on the manipulation of SHP as an approach in
the treatment of metabolic bone diseases such as osteoporosis.
As of now, a natural ligand of SHP has not been identified,
although one research group has proposed adamantyl-sub-
stituted retinoid-related molecules as potent regulators of
SHP.
(48) Thus it is important to pursue the identification of
specific ligand(s) or agonist(s) of SHP, the identity of which will
provide valuable tools for controlling bone metabolism.
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